NCT04847453 2026-04-13
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
8 trialsNCT03283917 2026-02-27
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04754945 2026-02-18
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Emory University
Phase 1 Active not recruiting
NCT06022939 2025-09-15
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
SWOG Cancer Research Network
Phase 3 Recruiting
NCT00520767 2023-12-22
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT03252600 2023-01-25
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Barbara Ann Karmanos Cancer Institute
Phase 2 Unknown
NCT01570387 2020-09-22
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Boston Medical Center
Phase 1/2 Completed
NCT00091260 2017-02-20
CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Boston Medical Center
Phase 2 Completed